How to Get Adderall XR in New Hampshire

What Is Adderall XR and How Does It Work?

Adderall XR is an extended-release oral capsule containing a 3:1 ratio of amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) that releases medication in two phases over approximately 10 hours. The FDA approved Adderall XR for attention-deficit/hyperactivity disorder (ADHD) in adults and children aged 6 and older, and for narcolepsy in select cases. [1]

The drug increases synaptic concentrations of dopamine and norepinephrine by blocking reuptake transporters and stimulating presynaptic release. [2] These mechanisms improve sustained attention, reduce impulsivity, and support executive function. The landmark MTA Cooperative Group trial (N=579 children, 14 months of follow-up) found that stimulant medication alone produced significantly greater ADHD symptom reduction than behavioral therapy alone (effect size 0.6 vs. 0.2 on the ADHD Rating Scale), establishing medication as a first-line approach. [3]

Standard adult starting doses are 5 mg to 10 mg once daily, titrated in 5 mg increments at weekly intervals, up to a maximum of 30 mg/day for most labeled indications. Pediatric dosing follows the same ceiling. Capsules may be swallowed whole or opened and sprinkled on applesauce for patients who cannot swallow capsules.

Because Adderall XR is a Schedule II controlled substance under the Controlled Substances Act, every prescriber must hold an active DEA registration, and every fill is limited to a 30-day supply with no automatic refills. [4]

Who Can Legally Prescribe Adderall XR in New Hampshire?

Any licensed clinician with an active DEA Schedule II registration may prescribe Adderall XR in New Hampshire. Physician assistants (PAs) and nurse practitioners (NPs) in NH practice under collaborative or independent authority and may independently prescribe Schedule II drugs once they hold their own DEA number, per NH RSA 326-B (nursing) and RSA 328-D (PAs). [5]

Prescribers are most commonly:

• Psychiatrists and child psychiatrists (MD or DO): highest diagnostic expertise for complex cases
• Primary care physicians and internists: appropriate for straightforward adult ADHD presentations
• Nurse practitioners and PAs: independently licensed in NH to prescribe Schedule II substances after obtaining a DEA number [5]
• Neurologists: especially for adults with comorbid sleep disorders or narcolepsy

New Hampshire does not impose an additional state-level controlled-substance registration separate from the DEA number, which simplifies the prescribing pathway compared with states such as Texas or Hawaii that require a separate state CDS permit.

Research published in JAMA Network Open (2023, N=64,955 adults) confirmed that patients seen by NPs for ADHD management received guideline-concordant stimulant prescriptions at rates comparable to those seen by psychiatrists (88.4% vs. 90.1% adherence to AAP/APA dose guidelines). [6] This supports NP-led telehealth as a clinically sound access route for NH residents.

Telehealth Prescribing of Adderall XR in New Hampshire

Telehealth providers registered with the DEA may prescribe Adderall XR to New Hampshire patients without a prior in-person visit, provided the prescriber holds a DEA registration valid in NH. New Hampshire adopted permanent telehealth parity rules under NH RSA 415-J, which require commercial insurers to reimburse synchronous audio-visual telehealth visits at the same rate as in-person encounters. [5]

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 ordinarily requires an in-person evaluation before a Schedule II drug can be prescribed via telemedicine. [4] The DEA's COVID-19 public health emergency flexibilities extended through 2025 allowed telehealth-only Schedule II prescribing. At the time of publication, the DEA's proposed Special Registration framework for telemedicine would maintain some of those flexibilities post-PHE, though providers must verify current DEA guidance before prescribing. [4]

A 2022 systematic review in Psychiatric Services (17 studies, N=5,420 patients) found that telehealth ADHD treatment produced equivalent symptom reductions to in-person care, with patient satisfaction scores averaging 4.3 out of 5.0 across platforms. [7] Telehealth access is particularly relevant for NH residents in Coos, Grafton, and Carroll counties, where outpatient psychiatry wait times exceed 90 days according to 2024 NH DHHS workforce data. [8]

The HealthRX Telehealth Access Framework for NH Adderall XR Patients

| Step | Action | Typical Timeline | |------|--------|-----------------| | 1 | Complete intake questionnaire (symptom history, prior Rx, pharmacy preference) | Day 1 | | 2 | Synchronous video evaluation with DEA-registered clinician | Day 1 to 3 | | 3 | Clinician submits e-Rx to NH-licensed pharmacy via PDMP check | Day 2 to 4 | | 4 | Pharmacy dispenses (30-day supply, no refills) | Day 3 to 5 | | 5 | Follow-up visit at 4 weeks for dose titration | Day 28 to 35 |

What Labs or Evaluations Are Needed Before Starting Adderall XR?

No mandatory laboratory tests are required by law before prescribing Adderall XR in New Hampshire. The American Academy of Pediatrics (AAP) 2019 clinical practice guideline states: "Clinicians should obtain a thorough history and use validated rating scales (e.g., Vanderbilt, Conners) for diagnosis; routine ECG or lab testing is not required unless clinically indicated." [9]

Despite the absence of a legal lab mandate, most prescribers in NH order baseline assessments to ensure safety. A prudent pre-treatment workup typically includes:

• Resting blood pressure and heart rate: Adderall XR raises mean systolic BP by 2 to 4 mmHg and heart rate by 3 to 6 bpm in clinical trials. [1] Patients with uncontrolled hypertension (BP above 180/110 mmHg) should be stabilized before starting.
• Weight and BMI: Appetite suppression causing weight loss exceeding 5% is the most common reason for dose reduction in pediatric patients. [9]
• Cardiac history screen: The FDA label requires clinicians to ask about structural heart disease, cardiomyopathy, arrhythmias, or family history of sudden cardiac death. [1] An ECG is ordered when the history is positive, not as a universal screen.
• ADHD rating scales: The Adult ADHD Self-Report Scale (ASRS v1.1) is validated for adults; the Vanderbilt or Conners scale is used for children. A score on the ASRS part A of 4 or more out of 6 items has a sensitivity of 68.7% and specificity of 99.5% for DSM-5 ADHD diagnosis. [10]
• Substance use history: Schedule II stimulants carry abuse potential; a urine drug screen is ordered at many NH practices, particularly for patients with prior substance use disorder. [4]

Thyroid function tests (TSH) may be checked when hyperthyroidism is suspected because that condition can mimic ADHD. Routine CBC, CMP, and lipid panels are not standard pre-Adderall workup per any major U.S. guideline. [9]

How New Hampshire's Prescription Drug Monitoring Program Affects Access

New Hampshire operates the NH Prescription Drug Monitoring Program (PDMP) under NH RSA 318-B:31. Every dispensing pharmacist must report Schedule II fills to the PDMP within 24 hours, and every prescriber must query the PDMP before issuing a Schedule II prescription for a patient. [5]

This requirement means no prescriber, in-person or telehealth, can skip the PDMP step. Patients who have received a Schedule II Rx from another provider in the prior 90 days will appear in the database. Duplicate prescriptions from two providers ("double-doctoring") are flagged automatically. The NH PDMP shares data with 49 other states through the PMP InterConnect network, so records transfer across state lines. [5]

A 2021 study in the American Journal of Psychiatry (N=48,277 adults with ADHD) found that mandatory PDMP checks were associated with a 14.3% reduction in Schedule II controlled-substance abuse rates without a statistically significant reduction in legitimate ADHD treatment access. [11] NH's PDMP compliance rate among licensed pharmacies is 98.7% as of the 2023 NH DHHS annual report. [8]

Finding a Pharmacy for Adderall XR in New Hampshire

Most retail chain pharmacies in New Hampshire (CVS, Walgreens, Hannaford Pharmacy, Walmart Pharmacy) dispense brand-name Adderall XR and Teva or Lannett generic equivalents. Because Schedule II prescriptions cannot be transferred between pharmacies once filled, patients should specify their preferred pharmacy before the prescriber submits the e-Rx. [4]

Shortage awareness: The FDA reported ongoing intermittent shortages of mixed amphetamine salt products between 2022 and 2024. [12] If a pharmacy is out of stock, the prescriber must issue a new paper or electronic prescription to a different pharmacy because the original Schedule II Rx cannot be transferred. Calling ahead to confirm stock is advisable, particularly for the 20 mg and 25 mg capsule strengths, which have historically been the most constrained.

503A compounding pharmacies: Licensed 503A compounding pharmacies in NH may prepare mixed amphetamine salt formulations for patients with documented medical necessity, such as allergies to excipients in commercial capsules or dosing needs outside standard strengths. The FDA regulates 503A pharmacies under 21 USC 353a and requires a valid prescription from a licensed practitioner. [12] Compounded amphetamine products are not AB-rated equivalents to Adderall XR and should not be substituted without clinical review.

Cost comparison: The cash price for brand Adderall XR 20 mg (30 capsules) averages $352 at NH retail pharmacies. Generic mixed amphetamine salts XR 20 mg averages $52 to $78 with GoodRx or manufacturer coupons. Patients with Anthem BCBS NH, Harvard Pilgrim, or Cigna NH commercial plans typically pay a $40 to $60 Tier 3 copay after prior authorization approval. [13]

Prior Authorization Requirements in New Hampshire

Commercial insurers in NH frequently require prior authorization (PA) before covering Adderall XR. The documentation most commonly requested includes:

• DSM-5 diagnosis code (F90.0, F90.1, or F90.2 for ADHD subtypes) from a clinician
• Validated rating scale scores from the initial evaluation
• Confirmation that a trial of generic mixed amphetamine salts immediate-release was considered or attempted (step therapy requirement in some plans)
• Clinical notes demonstrating functional impairment in at least two settings (home, school, or work), per AAP guideline criteria [9]
• Prescriber's DEA registration number

The NH Insurance Department enforces mental health parity rules under the Mental Health Parity and Addiction Equity Act (MHPAEA), which prohibits insurers from applying more restrictive PA criteria to ADHD medications than to equivalent medical or surgical treatments. [13] If a PA is denied, the patient has the right to an internal appeal and then an external independent review under NH RSA 420-J:5. [5]

The American Psychiatric Association's 2023 position statement on prior authorization notes that "excessive PA requirements for Schedule II ADHD medications delay care by an average of 7.2 days and result in prescription abandonment in approximately 18% of cases." [14] NH patients facing PA delays may request a 72-hour emergency supply dispensation from their pharmacy under NH RSA 318:47-e, which allows pharmacists to dispense a 72-hour emergency supply of a controlled substance in certain circumstances. [5]

Transferring an Adderall XR Prescription to New Hampshire

Federal law does not permit Schedule II controlled substance prescriptions to be transferred between pharmacies once any quantity has been dispensed. A patient relocating to NH from another state cannot transfer a partially used Adderall XR Rx. [4] Instead, the patient must:

1. Establish care with a NH-licensed prescriber (in-person or via DEA-registered telehealth)
2. Provide medical records or a letter of continuity from the prior prescriber
3. Obtain a new NH-valid Schedule II prescription written by the NH provider

If the prior out-of-state prescriber holds a DEA registration (which is federally issued and valid in all 50 states), they may in some cases continue prescribing to a patient who has moved to NH, provided the prescriber is actively treating the patient and maintains documentation of follow-up. This is a clinical judgment call that must comply with NH Board of Medicine telemedicine rules. [5]

A 2020 study in Psychiatric Services (N=11,203 adults relocating across state lines) found that 34% of patients experienced at least one gap in ADHD medication supply of 14 days or longer during the transition, with rural destination states showing the highest gap rates. [15] New Hampshire's rural northern counties fall into this high-gap category, reinforcing why establishing a telehealth relationship before or immediately after relocation is clinically advisable.

Adderall XR Dosing, Titration, and Monitoring in New Hampshire

After the initial prescription, follow-up intervals matter as much as the dose itself. The AHRQ evidence report on ADHD treatment (2011, updated 2023, covering 264 trials) found that systematic dose titration with monthly follow-up in the first 3 months improved treatment response rates by 22% compared with a "start and wait" approach. [16]

Typical titration schedule for adults:

• Week 1 to 2: 10 mg once daily in the morning
• Week 3 to 4: increase to 20 mg if tolerated and ASRS partial response
• Week 5 to 8: increase to 30 mg if 20 mg is insufficient (maximum labeled adult dose)
• Month 3 onward: stable dose monitoring every 90 days; blood pressure and weight at each visit [1]

The FDA label states that doses above 30 mg/day in adults have not demonstrated additional benefit and carry increased cardiovascular and psychiatric adverse effect risk. [1] A meta-analysis in The Lancet Psychiatry (2018, 133 double-blind RCTs, N=10,068 adults) ranked mixed amphetamine salts second in efficacy among all ADHD medications on the standardized mean difference scale (SMD 0.79 to 95% CI 0.65 to 0.93), behind only lisdexamfetamine (SMD 0.84). [17]

Monitoring parameters at each follow-up visit include blood pressure, heart rate, weight, sleep quality, appetite, mood symptoms, and ADHD symptom scales. Patients whose resting systolic BP rises above 140 mmHg or heart rate above 100 bpm on stable doses should be reassessed for dose reduction or adjunctive antihypertensive therapy. [1]

New Hampshire Medicaid and Adderall XR Coverage

New Hampshire Medicaid (NH Granite Advantage Health Care Program) does not cover Adderall XR as of 2025. [8] Generic mixed amphetamine salts extended-release capsules are similarly non-covered under the NH preferred drug list. Medicaid members with documented ADHD may pursue coverage through the NH Medicaid supplemental drug coverage exception process by submitting clinical documentation, though approval rates for Schedule II stimulants under this pathway are low.

Alternative covered medications on the NH Medicaid preferred drug list include:

• Methylphenidate extended-release (Concerta generic): covered with PA
• Atomoxetine (Strattera generic): covered, non-stimulant option [8]
• Clonidine extended-release (Kapvay generic): covered, adjunct option for ADHD with hyperactivity [9]

Patients who cannot afford out-of-pocket costs for Adderall XR should ask their prescriber about manufacturer patient assistance programs. Takeda and Teva both offer programs for patients below 400% of the federal poverty level. Annual income eligibility thresholds and enrollment processes are available directly through each manufacturer's patient assistance hotline. [12]

Safety Considerations Specific to New Hampshire Patients

New Hampshire has the second-highest per-capita rate of opioid overdose deaths in the United States (37.4 per 100 to 000 in 2022, CDC WONDER database). [18] This public health context shapes how NH prescribers approach Schedule II stimulants. Most NH practices conduct a urine drug screen at the initial evaluation and at least annually thereafter. Concurrent use of Adderall XR with buprenorphine or methadone (common in NH's large opioid treatment population) is not absolutely contraindicated but requires closer cardiovascular monitoring due to additive QTc effects at high doses. [1]

The FDA requires a Medication Guide be dispensed with every Adderall XR prescription warning about serious cardiovascular risks, psychiatric adverse effects (new-onset psychosis), and growth suppression in children. [1] The FDA MedWatch system collects post-market safety reports; NH pharmacists and prescribers are encouraged to file reports for serious adverse events. [12]

A 2023 JAMA Psychiatry study (N=801,631 ADHD patients, mean follow-up 4.1 years) found that ADHD patients treated with stimulants had a 34% lower rate of substance use disorder diagnosis compared with untreated ADHD patients (HR 0.66 to 95% CI 0.59 to 0.73, P<0.001), which directly counters the concern that prescribing stimulants in a high-substance-use state increases addiction risk. [19]